This study aimed to assess the effectiveness of current lipid-lowering therapy in achieving low-density lipoprotein cholesterol (LDL-C) goals in Indian patients undergoing coronary revascularization. Consecutive subjects (n = 1275, mean age 60.0 ± 9.7 years, 87.2 % men) with newly diagnosed coronary artery disease and undergoing coronary revascularization during the period 1 Jan 2023 to 31 Dec 2023 were included. After a median follow-up of 99 days (interquartile range 91-109 days), the mean LDL-C was 63.9 ± 24.3 mg/dL with 67.5% and 29.9% of subjects having LDL-C <70 mg/dL and <50 mg/dL, respectively. These proportions were 70.8% and 32.1% for patients treated with high-intensity statin therapy (rosuvastatin 20-40 mg/d or atorvastatin 40-80 mg/d). Among patients treated with rosuvastatin 40 mg/d and ezetimibe 10 mg/d, 53.3% achieved LDL-C <50 mg/dL. These findings underscore the need for greater usage of combination lipid-lowering therapy and agents with high LDL-C lowering efficacy.
Keywords: Atherosclerotic cardiovascular disease; Bempedoic acid; Ezetimibe; High-intensity statin therapy.
Copyright © 2024 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.